SYNTEX STARTS NDA FILE FOR NICARDIPINE IN ANGINE
Executive Summary
SYNTEX STARTS NDA FILE FOR NICARDIPINE IN ANGINE with the June submission of the chemistry and pharmacy sections of the NDA for the calcium channel blocker. Syntex Chairman and CEO Albert Bowers told New York security analysts on June 12 that the company expects to file the remainder of the application this summer. An NDA for the hypertension indication for the drug, licensed from Yamanouchi, is expected to be filed "early in calendar year 1986," he added. Under the NDA rewrite regulations, companies can submit the chemistry and pharmacy section of a NDA 90 to 120 days in advance of the remainder of the application. FDA review of the information is supposed to begin immediately with the first filing. Nicardipine is the second drug for which Syntex has used the expedited filing procedure. Syntex' NDA submission for Gardrin (enprostil), for treatment of duodenal ulcer, was begun in April and is expected to be completed in July, the company said. At present, Knoll's Isoptin (verapamil), co-marketed by Searle, has a head start on the other calcium channel blockers toward receiving a hypertension claim in the U.S. FDA's Cardio-Renal Advisory Cmte. recommended the drug for approval in hypertension on April 11 ("The Pink Sheet" April 15, p. 10). Rizer (Procardia) and Marion (Cardizen) have both indicated they will file for hypertension in 1985. Bayer's U.S. subsidiary, Miles, may be able to market nifedipine in the U.S. in 1986 when the clock on Pfizer's exclusive license to market the drug is expected to run out. Outside of the U.S., Bayer sells the drug under the name, Adalat. Bayer has reportedly filed an NDA in the U.S. for its second generation calcium channel blocker nitrendipine in hypertension. Nitrendipine was approved for marketing last February in West Germany, where it was launched in April as Bayotensin for hypertension. Nitrendipine is in the registration process in several other countries. Recommended dosage of the drug in Germany, is one 20 mg tablet daily.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth